One dose of prefusion F protein–based vaccine for older adults administered to ≥60-year-olds induced humoral and cell-mediated immune responses that remained above pre–dose 1 levels for at least 1 year. The vaccine was well tolerated with an acceptable safety profile.
All Keywords
【저자키워드】 immunogenicity, Safety, Older adults, respiratory syncytial virus, phase 3 study,
【저자키워드】 immunogenicity, Safety, Older adults, respiratory syncytial virus, phase 3 study,